Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On”

Group 1 - Insmed Incorporated (NASDAQ:INSM) is a biopharma company that focuses on developing drugs for rare diseases, achieving a stock performance increase of 152% last year, making it the fifth best performer in the Nasdaq-100 [1] - The company received FDA approval for a treatment targeting non-cystic fibrosis bronchiectasis, which is considered a powerful anti-inflammatory drug [1] - Despite a recent pullback of approximately 18% from its December peak due to disappointing clinical trial results in chronic sinusitis, Insmed remains a company to watch [1] Group 2 - Insmed develops and commercializes therapies for serious and rare diseases, including an approved treatment for complex lung infections and several late and mid-stage clinical programs [2]